LCTX

1.29

0.77% -0.01

Dopo l'orario di chiusura: 1.30 0.01 +0.78%

Lineage Cell Therapeutics Inc (LCTX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Forum Previsione Frazionamento azionario

Precedente Chiudi:

$1.30

Aprire:

$1.3

Volume 24 ore:

1.23M

Relative Volume:

1.01

Capitalizzazione di mercato:

$321.59M

Reddito:

$14.56M

Utile/perdita netta:

$-63.37M

Rapporto P/E:

-4.6353

EPS:

-0.2783

Flusso di cassa netto:

$-19.44M

1 W Prestazione:

+7.50%

1M Prestazione:

-16.77%

6M Prestazione:

-24.56%

1 anno Prestazione:

+84.63%

Intervallo 1D:

$1.27

$1.34

Intervallo di 1 settimana:

$1.20

$1.365

Portata 52W:

$0.64

$2.09

Lineage Cell Therapeutics Inc Stock (LCTX) Company Profile

Nome

Lineage Cell Therapeutics Inc

Settore

Healthcare (1111)

Industria

Biotechnology (621)

Telefono

510-871-4188

Indirizzo

2173 Salk Avenue, Suite 200, Carlsbad, CA

Dipendente

Cinguettio

@LineageCell

Prossima data di guadagno

2026-05-12

Ultimi documenti SEC

LCTX's Discussions on Twitter

Compare LCTX vs VRTX, REGN, ARGX, ALNY, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
LCTX Lineage Cell Therapeutics Inc	1.29	324.09M	14.56M	-63.37M	-19.44M	-0.2783
VRTX Vertex Pharmaceuticals Inc	435.93	110.28B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	634.62	66.98B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	808.43	50.15B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	295.50	39.71B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	154.89	32.22B	742.00K	-1.37B	-1.07B	-7.0731

Lineage Cell Therapeutics Inc Stock (LCTX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-08-20	Iniziato	Craig Hallum	Buy
2022-11-02	Iniziato	Robert W. Baird	Outperform
2022-06-14	Iniziato	B. Riley Securities	Buy
2021-08-19	Iniziato	Noble Capital Markets	Outperform
2021-03-31	Iniziato	Cantor Fitzgerald	Overweight

Lineage Cell Therapeutics Inc Borsa (LCTX) Ultime notizie

07:15 AM

Earnings Preview: LCTX to Report Financial Results Post-market on May 12 - Moomoo

May 21, 2026

May 20, 2026

Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets - Investing News Network

May 20, 2026

May 18, 2026

Lineage Cell Therapeutics, Inc. Common Stock (NY: LCTX - FinancialContent

May 18, 2026

Lineage Cell Therapeutics, Inc. Common Stock (NYSE:LCTX) Stock Quote - FinancialContent

May 18, 2026

May 15, 2026

Lineage Cell Therapeutics Q1 Earnings Call Highlights - sharewise.com

May 15, 2026

May 14, 2026

Lineage Cell Therapeutics Q1 2026 earnings preview - MSN

May 14, 2026

Lineage Cell Therapeutics featured in European Pharmaceutical Review report on scalable cell therapies - Traders Union

May 14, 2026

Lineage Cell Therapeutics (LCTX) Returns To Loss In Q1 2026 Challenging Profitability Narratives - Sahm

May 14, 2026

May 13, 2026

Lineage Cell Therapeutics Highlights R&D Momentum Amid Losses - TipRanks

May 13, 2026

Q1 2026 Lineage Cell Therapeutics Inc Earnings Call Transcript - GuruFocus

May 13, 2026

Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q1 2026 Earnings Call Transcript - Insider Monkey

May 13, 2026

Lineage targets operations into Q2 2028 as it launches COR1 and scales ILT1 manufacturing - MSN

May 13, 2026

Lineage Cell (LCTX) reports Q1 loss, lags revenue estimates - MSN

May 13, 2026

Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update - BioSpace

May 13, 2026

Lineage Cell Therapeutics (LCTX) Reports Q1 2026 Earnings and St - GuruFocus

May 13, 2026

TradingKey - TradingKey

May 13, 2026